Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Commercialization phase - Jan 2023 to December 2025

<< Previous

Bullboard Posts

Next >>

Comment by LaserStock29on May 04, 2022 1:56pm

181 Views

Post# 34655698

RE:RE:Commercialization phase - Jan 2023 to December 2025

Just hope we got a sweet $2 pps by the agm

Eoganacht wrote: That's how I see it too. I think Theralase is expecting to be granted accelerated approval in early 2023 so they can begin commercialization. The rest of the trial will just serve to confirm the clinical benefit that was the basis for early approval.

ScienceFirst wrote: P. 12 of the most recent presentation shows that they expect Breakthrough designation a bit before 2022 year's end. Like around late November. They also expect "commercialization phase" starting Jan. 2023, through December 2025.

Given that FDA and HC approval is due late 2025, my take is that they expect to have Breakthrough AND Accelerated Approval (AA) early 2023 (i.e Januray 2023) and that this "commercialization phase" would bring revenues, whether from AA designation or from an upfront payment related to a jv (a jv deal that would already be agreed upon). There's no other reasons that could explain this "commercialization phase". That's the only rational explanation. So valuation is coming soon.

Theralase corporate presentation - April 22, 2022